Ning Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ning Li has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Haitao Zhang
Department of General Surgery Center, Beijing YouAn Hospital Capital Medical University Beijing China
2 shared publicationsBoxun Jin
Department of Hepatobiliary Surgery, YouAn Hospital Affiliated to Capital Medical University, Beijing, China
1 shared publicationJian Li
Department of Hepatobiliary Surgery, YouAn Hospital Affiliated to Capital Medical University, Beijing, China
1 shared publication- Shichun Lu
Nankai University School of Medicine, Tianjin, China
1 shared publication Tiezheng Wang
Department of Hepatobiliary Surgery, YouAn Hospital Affiliated to Capital Medical University, Beijing, China
1 shared publicationWenlei Li
Department of Hepatobiliary Surgery, YouAn Hospital Affiliated to Capital Medical University, Beijing, China
1 shared publication
Latest Publications
- 10 February 2021
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 36 (7) , 1769-1777
Evaluation of clinical outcomes of radiofrequency ablation and surgical resection for hepatocellular carcinoma conforming to the Milan criteria: A systematic review and meta‐analysis of recent randomized controlled trials
Background and Aim: The few systematic reviews that have compared surgical resection (SR) with radiofrequency ablation (RFA) indicated that hepatectomy was superior to RFA in the treatment of hepatocellular carcinoma (HCC) irrespective of overall survival (OS) or disease‐free survival (DFS). However, randomized controlled trials (RCTs) are scarce; therefore, there is a lack of robust evidence on the optimal first‐line treatment for HCC patients. The purpose of this study was to include all current RCT studies to compare the clinical efficacy between RFA and SR in patients with HCC who meet the Milan criteria using meta‐analysis techniques.Methods: We conducted thorough searches of PubMed, Embase, Cochrane, Web of Knowledge, FDA.gov, and ClinicalTrials.gov for comparative studies (published between 1 January 1996 and 31 December 2019; no language restrictions) of RFA and SR. The main endpoints were OS, DFS, and postoperative complications. Only randomized clinical trials were included. The odds ratios (OR) were pooled and calculated with 95% confidence intervals (CI) for both fixed effects and random effects models.Results: Eight studies comparing RFA and SR were identified, which included 1177 patients treated with RFA (n = 571) or SR (n = 606). The OR values for patients treated with RFA and SR at 1, 3, and 5 years were OR: 0.91, 95% CI: 0.45–1.38; OR: 0.82, 95% CI: 0.56–1.19; and OR: 1.03, 95% CI: 0.61–1.73, respectively. The OS between the two treatments was not significantly different. The 1‐year DFS rates resulting from the two treatments were not statistically different (OR: 0.87, 95% CI: 0.63–1.21). Similarly, according to long‐term DFS rates for SR compared with RFA, although the OR value was less than 1, there was no statistical significance (OR: 0.79, 95% CI: 0.58–1.07). However, it is worth noting that RFA has advantages over SR in terms of treatment‐related complications (OR: 0.65, 95% CI: 0.44–0.80; P < 0.05), postoperative mortality, length of stay, and hospitalization costs.Conclusion: For patients with HCC who meet the Milan criteria, RFA exhibited similar clinical efficacy to SR. However, RFA was superior to SR in terms of minor trauma and may be recommended as the first choice for tumors ≤ 4 cm in diameter.
- 10 February 2021
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 36 (7) , 1769-1777
Evaluation of clinical outcomes of radiofrequency ablation and surgical resection for hepatocellular carcinoma conforming to the Milan criteria: A systematic review and meta‐analysis of recent randomized controlled trials
Background and Aim: The few systematic reviews that have compared surgical resection (SR) with radiofrequency ablation (RFA) indicated that hepatectomy was superior to RFA in the treatment of hepatocellular carcinoma (HCC) irrespective of overall survival (OS) or disease‐free survival (DFS). However, randomized controlled trials (RCTs) are scarce; therefore, there is a lack of robust evidence on the optimal first‐line treatment for HCC patients. The purpose of this study was to include all current RCT studies to compare the clinical efficacy between RFA and SR in patients with HCC who meet the Milan criteria using meta‐analysis techniques.Methods: We conducted thorough searches of PubMed, Embase, Cochrane, Web of Knowledge, FDA.gov, and ClinicalTrials.gov for comparative studies (published between 1 January 1996 and 31 December 2019; no language restrictions) of RFA and SR. The main endpoints were OS, DFS, and postoperative complications. Only randomized clinical trials were included. The odds ratios (OR) were pooled and calculated with 95% confidence intervals (CI) for both fixed effects and random effects models.Results: Eight studies comparing RFA and SR were identified, which included 1177 patients treated with RFA (n = 571) or SR (n = 606). The OR values for patients treated with RFA and SR at 1, 3, and 5 years were OR: 0.91, 95% CI: 0.45–1.38; OR: 0.82, 95% CI: 0.56–1.19; and OR: 1.03, 95% CI: 0.61–1.73, respectively. The OS between the two treatments was not significantly different. The 1‐year DFS rates resulting from the two treatments were not statistically different (OR: 0.87, 95% CI: 0.63–1.21). Similarly, according to long‐term DFS rates for SR compared with RFA, although the OR value was less than 1, there was no statistical significance (OR: 0.79, 95% CI: 0.58–1.07). However, it is worth noting that RFA has advantages over SR in terms of treatment‐related complications (OR: 0.65, 95% CI: 0.44–0.80; P < 0.05), postoperative mortality, length of stay, and hospitalization costs.Conclusion: For patients with HCC who meet the Milan criteria, RFA exhibited similar clinical efficacy to SR. However, RFA was superior to SR in terms of minor trauma and may be recommended as the first choice for tumors ≤ 4 cm in diameter.
- 2 August 2018
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 33 (4) , 353-363
Diagnosis accuracy of serum glypican-3 level in patients with hepatocellular carcinoma: a systematic review with meta-analysis
Background: Previous studies have evaluated the diagnostic value of serum glypican-3 in patients with hepatocellular carcinoma. However, the results remain inconsistent and even controversial. Thus, the aim of the present meta-analysis was to clarify the diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma. Methods: A meta-analysis including 22 studies was performed with 2325 cases and 2280 controls. Relevant studies were searched in the EMBASE, PubMed, and Web of Science databases, covering relevant papers published until November 1, 2017. The quality of the studies was assessed by revised QUADAS tools. Sensitivity, specificity, and other measures were pooled and determined to evaluate the accuracy of serum glypican-3 in the diagnosis of hepatocellular carcinoma by random-effects models. Summary receiver operating characteristic curve (sROC) analysis was performed to summarize the overall test performance. Results: The results showed that the pooled overall diagnostic sensitivity, specificity, and 95% confidence interval (CI) for serum glypican-3 in the diagnosis of hepatocellular carcinoma were 68% (56-79%) and 92% (82-96.0%), respectively. Besides, the summary diagnostic odds ratio and 95% CI for glypican-3 were 23.53 (8.57-64.63). In addition, the area under sROC and 95% CI was 0.87 (0.84-0.90). The major design deficiencies of included studies were differential verification bias, and a lack of clear exclusion and inclusion criteria. Conclusions: The results of this meta-analysis suggested that serum glypican-3 was acceptable as a moderate diagnostic marker in the diagnosis of hepatocellular carcinoma compared with healthy individuals, which could elevate the sensitivity and specificity of diagnosis. Furthermore, more well-designed studies with large sample sizes are needed to show the effectiveness of glypican-3 in the differential diagnosis of hepatocellular carcinoma.
- 2 August 2018
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 33 (4) , 353-363
Diagnosis accuracy of serum glypican-3 level in patients with hepatocellular carcinoma: a systematic review with meta-analysis
Background: Previous studies have evaluated the diagnostic value of serum glypican-3 in patients with hepatocellular carcinoma. However, the results remain inconsistent and even controversial. Thus, the aim of the present meta-analysis was to clarify the diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma. Methods: A meta-analysis including 22 studies was performed with 2325 cases and 2280 controls. Relevant studies were searched in the EMBASE, PubMed, and Web of Science databases, covering relevant papers published until November 1, 2017. The quality of the studies was assessed by revised QUADAS tools. Sensitivity, specificity, and other measures were pooled and determined to evaluate the accuracy of serum glypican-3 in the diagnosis of hepatocellular carcinoma by random-effects models. Summary receiver operating characteristic curve (sROC) analysis was performed to summarize the overall test performance. Results: The results showed that the pooled overall diagnostic sensitivity, specificity, and 95% confidence interval (CI) for serum glypican-3 in the diagnosis of hepatocellular carcinoma were 68% (56-79%) and 92% (82-96.0%), respectively. Besides, the summary diagnostic odds ratio and 95% CI for glypican-3 were 23.53 (8.57-64.63). In addition, the area under sROC and 95% CI was 0.87 (0.84-0.90). The major design deficiencies of included studies were differential verification bias, and a lack of clear exclusion and inclusion criteria. Conclusions: The results of this meta-analysis suggested that serum glypican-3 was acceptable as a moderate diagnostic marker in the diagnosis of hepatocellular carcinoma compared with healthy individuals, which could elevate the sensitivity and specificity of diagnosis. Furthermore, more well-designed studies with large sample sizes are needed to show the effectiveness of glypican-3 in the differential diagnosis of hepatocellular carcinoma.
- 1 August 2011
- Published by Wolters Kluwer Health
- Vol. 19 (8) , 628-9
[3 cases with idiopathic portal hypertension: a review of literature].
- 1 August 2011
- Published by Wolters Kluwer Health
- Vol. 19 (8) , 628-9
[3 cases with idiopathic portal hypertension: a review of literature].